Boston Scientific shows strong profit growth:
This article was originally published in Clinica
Boston Scientific has wiped out its first-half loss with net income of $47 million in the third quarter, up 29% on the previous year. In the first nine months net income was $24.3 million compared with $52.6 million a year earlier. Boston's third-quarter sales were 29% higher at $232.8 million and 28% up at $675.8 million in the first nine months. CEO Pete Nicholas says Boston had "excellent results in both vascular and non-vascular businesses". The three acquisitions this autumn - EP Technologies, Meadox Medicals and Heart Technology - will "further improve Boston's strategic position" in less invasive medicine, Mr Nicholas adds.